Size : 10mM(in1mLDMSO)
Request more information
Please log in to use this feature.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Cell lines
PBMCs
Preparation method
The solubility of this compound in DMSO is > 11.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting condition
0 ~ 100 μg/mL
Applications
Thalidomide dose-dependently increased the proliferative responses of PBMCs stimulated by immobilized anti-CD3. As the concentration of anti-CD3 increased, Thalidomide at a constant concentration of 10 μg/mL significantly induced the proliferative responses of PBMCs. However, Thalidomide exhibited no effect on the proliferative response in the absence of anti-CD3. These results indicated that Thalidomide was not mitogenic, Instead, it acted as a costimulator.
Animal models
Rabbits
Dosage form
200 mg/kg; p.o.
In rabbits, Thalidomide at the dose of 200 mg/kg inhibited the area of vascularized cornea, with a median inhibition of 36%. The inhibition of Thalidomide on angiogenesis was seen after only two doses. In addition, the rabbits did not show significant sedation, and there were no signs of toxicity or weight loss.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998 Jun 1;187(11):1885-92.
[2]. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5.
